First-line pemetrexed-platinum doublet chemotherapy with or without bevacizumab in non-squamous non-small cell lung cancer: A real-world propensity score-matched study in China

Documenti analoghi

• Phase II Study of a Non-platinum-containing Doublet of Paclitaxel and Pemetrexed with Bevacizumab (PPB) as Initial Therapy for Patients with Advanced Lung Adenocarcinomas
  di: Pietanza, Catherine M., et al.
  Pubblicazione: (2016)
• A phase II randomized trial evaluating gefitinib intercalated with pemetrexed/platinum chemotherapy or pemetrexed/platinum chemotherapy alone in unselected patients with advanced non-squamous non-small cell lung cancer
  di: Yu, Hui, et al.
  Pubblicazione: (2014)
• Doublet chemotherapy with cisplatin and pemetrexed is associated with a favorable outcome in patients with advanced non-squamous non-small-cell lung cancer who are eligible for bevacizumab and maintenance therapy
  di: Nakashima, Kazuhisa, et al.
  Pubblicazione: (2016)
• High plasma exposure to pemetrexed leads to severe hyponatremia in patients with advanced non small cell lung cancer receiving pemetrexed-platinum doublet chemotherapy
  di: Gota, Vikram, et al.
  Pubblicazione: (2014)
• A prognostic model for platinum‐doublet as second‐line chemotherapy in advanced non‐small‐cell lung cancer patients
  di: Mo, Hongnan, et al.
  Pubblicazione: (2016)